CN113289002A - 神经调节蛋白用于预防、治疗或延缓心力衰竭的方法和组合物 - Google Patents

神经调节蛋白用于预防、治疗或延缓心力衰竭的方法和组合物 Download PDF

Info

Publication number
CN113289002A
CN113289002A CN202010174086.5A CN202010174086A CN113289002A CN 113289002 A CN113289002 A CN 113289002A CN 202010174086 A CN202010174086 A CN 202010174086A CN 113289002 A CN113289002 A CN 113289002A
Authority
CN
China
Prior art keywords
heart failure
neuregulin
treatment
probnp
nrg
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202010174086.5A
Other languages
English (en)
Chinese (zh)
Inventor
周明东
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zensun Shanghai Science and Technology Ltd
Original Assignee
Zensun Shanghai Science and Technology Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zensun Shanghai Science and Technology Ltd filed Critical Zensun Shanghai Science and Technology Ltd
Priority to US17/799,252 priority Critical patent/US20230083149A1/en
Priority to PCT/CN2021/076772 priority patent/WO2021169845A1/zh
Priority to KR1020227032863A priority patent/KR20220145870A/ko
Priority to CA3172439A priority patent/CA3172439A1/en
Priority to AU2021225283A priority patent/AU2021225283A1/en
Priority to EP21761756.2A priority patent/EP4115899A4/en
Priority to JP2022550720A priority patent/JP7807815B2/ja
Publication of CN113289002A publication Critical patent/CN113289002A/zh
Priority to JP2025205790A priority patent/JP2026062640A/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1883—Neuregulins, e.g.. p185erbB2 ligands, glial growth factor, heregulin, ARIA, neu differentiation factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G01N2333/4756—Neuregulins, i.e. p185erbB2 ligands, glial growth factor, heregulin, ARIA, neu differentiation factor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G01N2333/58—Atrial natriuretic factor complex; Atriopeptin; Atrial natriuretic peptide [ANP]; Brain natriuretic peptide [BNP, proBNP]; Cardionatrin; Cardiodilatin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/325—Heart failure or cardiac arrest, e.g. cardiomyopathy, congestive heart failure
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cardiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Saccharide Compounds (AREA)
CN202010174086.5A 2020-02-24 2020-03-13 神经调节蛋白用于预防、治疗或延缓心力衰竭的方法和组合物 Pending CN113289002A (zh)

Priority Applications (8)

Application Number Priority Date Filing Date Title
US17/799,252 US20230083149A1 (en) 2020-02-24 2021-02-19 Method for preventing, treating or delaying heart failure by using neuregulin, and composition
PCT/CN2021/076772 WO2021169845A1 (zh) 2020-02-24 2021-02-19 神经调节蛋白用于预防、治疗或延缓心力衰竭的方法和组合物
KR1020227032863A KR20220145870A (ko) 2020-02-24 2021-02-19 뉴레귤린, 및 조성물을 사용함으로써 심부전을 예방, 치료 또는 지연시키기 위한 방법
CA3172439A CA3172439A1 (en) 2020-02-24 2021-02-19 Method for preventing, treating or delaying heart failure by using neuregulin, and composition
AU2021225283A AU2021225283A1 (en) 2020-02-24 2021-02-19 Method for preventing, treating or delaying heart failure by using neuregulin, and composition
EP21761756.2A EP4115899A4 (en) 2020-02-24 2021-02-19 Method for preventing, treating or delaying heart failure by using neuregulin, and composition
JP2022550720A JP7807815B2 (ja) 2020-02-24 2021-02-19 ニューレグリンの使用による心不全を予防、治療、又は遅延させるための方法及び組成物
JP2025205790A JP2026062640A (ja) 2020-02-24 2025-11-27 ニューレグリンの使用による心不全を予防、治療、又は遅延させるための方法及び組成物

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN202010113391 2020-02-24
CN2020101133913 2020-02-24

Publications (1)

Publication Number Publication Date
CN113289002A true CN113289002A (zh) 2021-08-24

Family

ID=77317937

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202010174086.5A Pending CN113289002A (zh) 2020-02-24 2020-03-13 神经调节蛋白用于预防、治疗或延缓心力衰竭的方法和组合物
CN202180015952.9A Pending CN115515620A (zh) 2020-02-24 2021-02-19 神经调节蛋白用于预防、治疗或延缓心力衰竭的方法和组合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202180015952.9A Pending CN115515620A (zh) 2020-02-24 2021-02-19 神经调节蛋白用于预防、治疗或延缓心力衰竭的方法和组合物

Country Status (8)

Country Link
US (1) US20230083149A1 (enExample)
EP (1) EP4115899A4 (enExample)
JP (2) JP7807815B2 (enExample)
KR (1) KR20220145870A (enExample)
CN (2) CN113289002A (enExample)
AU (1) AU2021225283A1 (enExample)
CA (1) CA3172439A1 (enExample)
WO (1) WO2021169845A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024067817A1 (zh) * 2022-09-30 2024-04-04 上海泽生科技开发股份有限公司 神经调节蛋白及其应用

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE463851B (sv) 1988-09-02 1991-02-04 Amsu Ltd Komposition foer behandling av erektil dysfunktion via uretra
US5530109A (en) 1991-04-10 1996-06-25 Ludwig Institute For Cancer Research DNA encoding glial mitogenic factors
US7115554B1 (en) 1993-05-06 2006-10-03 Acorda Therapeutics, Inc. Methods of increasing myotube formation or survival or muscle cell mitogenesis differentiation or survival using neuregulin GGF III
US5716930A (en) 1991-04-10 1998-02-10 Ludwig Institute For Cancer Research Glial growth factors
US5834229A (en) 1991-05-24 1998-11-10 Genentech, Inc. Nucleic acids vectors and host cells encoding and expressing heregulin 2-α
DE4221256C2 (de) 1992-06-26 1997-07-10 Lancaster Group Ag Galenische Zusammensetzung für die topische Anwendung
US5741511A (en) 1995-04-12 1998-04-21 Sam Yang Co., Ltd. Transdermal drug delivery device for treating erectile dysfunction
US5912326A (en) 1995-09-08 1999-06-15 President And Fellows Of Harvard College Cerebellum-derived growth factors
JP2000502682A (ja) 1995-12-22 2000-03-07 ローカルメッド インコーポレイテッド 血管新生を促進する成長因子の局所的血管内デリバリー
SE9703226D0 (sv) 1997-09-08 1997-09-08 Astra Ab New pharmaceutical composition
EP1028735A4 (en) 1997-10-14 2003-08-06 Cenes Pharmaceuticals Inc THERAPEUTIC METHOD COMPRISING THE USE OF NEUREGULIN
AUPP785098A0 (en) 1998-12-21 1999-01-21 Victor Chang Cardiac Research Institute, The Treatment of heart disease
US6635249B1 (en) 1999-04-23 2003-10-21 Cenes Pharmaceuticals, Inc. Methods for treating congestive heart failure
CN1138785C (zh) 1999-06-04 2004-02-18 周明东 生长因子神经调节蛋白及其类似物的新应用
AU2002304965A1 (en) 2002-05-24 2003-12-12 Zensun (Shanghai) Sci-Tech.Ltd Neuregulin based methods and compositions for treating viral myocarditis and dilated cardiomyopathy
CN104436167A (zh) * 2010-06-12 2015-03-25 上海泽生科技开发有限公司 神经调节蛋白用于治疗心力衰竭的有效剂量
WO2013053076A1 (en) * 2011-10-10 2013-04-18 Zensun （Shanghai）Science & Technology Limited Compositions and methods for treating heart failure
US20160129084A1 (en) * 2013-03-06 2016-05-12 Acorda Therapeutics, Inc. Therapeutic Dosing of a Neuregulin or a Fragment Thereof for Treatment or Prophylaxis of Heart Failure
CN111407882A (zh) * 2014-10-17 2020-07-14 上海泽生科技开发股份有限公司 神经调节蛋白用于预防、治疗或延迟射血分数保留的心力衰竭的方法和组合物
CN110835368A (zh) * 2018-08-15 2020-02-25 上海泽生科技开发股份有限公司 神经调节蛋白多肽片段及其用途

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024067817A1 (zh) * 2022-09-30 2024-04-04 上海泽生科技开发股份有限公司 神经调节蛋白及其应用

Also Published As

Publication number Publication date
JP2023514738A (ja) 2023-04-07
CN115515620A (zh) 2022-12-23
EP4115899A4 (en) 2024-03-06
JP2026062640A (ja) 2026-04-10
US20230083149A1 (en) 2023-03-16
CA3172439A1 (en) 2021-09-02
EP4115899A1 (en) 2023-01-11
JP7807815B2 (ja) 2026-01-28
WO2021169845A1 (zh) 2021-09-02
KR20220145870A (ko) 2022-10-31
AU2021225283A1 (en) 2022-09-15

Similar Documents

Publication Publication Date Title
JP7761964B2 (ja) 心不全の治療用組成物
CN102470161A (zh) 神经调节蛋白用于治疗心力衰竭的有效剂量
JP2026062640A (ja) ニューレグリンの使用による心不全を予防、治療、又は遅延させるための方法及び組成物
HK40086556A (en) Method for preventing, treating or delaying heart failure by using neuregulin, and composition
HK1231890B (en) Neuregulin for treating heart failure
HK1231890A1 (en) Neuregulin for treating heart failure

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination